<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60908</article-id><article-id pub-id-type="doi">10.7554/eLife.60908</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-196956"><name><surname>Ma</surname><given-names>Ying Jie</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4003-2579</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197825"><name><surname>Zhang</surname><given-names>Jie</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4472-3468</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197824"><name><surname>Song</surname><given-names>Lihong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197823"><name><surname>Pedersen</surname><given-names>Dennis V</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197822"><name><surname>Li</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197821"><name><surname>Lambris</surname><given-names>John D.</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-99560"><name><surname>Andersen</surname><given-names>Gregers Rom</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6292-3319</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197820"><name><surname>Mollnes</surname><given-names>Tom Eirik</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-197819"><name><surname>Garred</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Clinical Immunology</institution>, <institution>Rigshospitalet/Copenhagen University</institution>, <addr-line><named-content content-type="city">Copenhagen</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff2"><institution content-type="dept">Department of Molecular Biology and Genetics</institution>, <institution>Aarhus University</institution>, <addr-line><named-content content-type="city">Aarhus</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff3"><institution content-type="dept">Department of Pathology and Laboratory Medicine</institution>, <institution>University of Pennsylvania</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Molecular Biology and Genetics</institution>, <institution>Aarhus University</institution>, <addr-line><named-content content-type="city">Aarhus</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff5"><institution content-type="dept">Department of Immunology</institution>, <institution>University of Oslo</institution>, <addr-line><named-content content-type="city">Oslo</named-content></addr-line>, <country>Norway</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-56354"><name><surname>van de Veerdonk</surname><given-names>Frank L</given-names></name><role>Reviewing editor</role><aff><institution>Radboud University Medical Center</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>ying.jie.ma@regionh.dk</email> (YM);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>peter.garred@regionh.dk</email> (PG);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>09</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e60908</elocation-id><history><date date-type="received"><day>09</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>09</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Ma et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Ma et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60908-v1.pdf"/><abstract><p>Properdin stabilizes the alternative C3 convertase (C3bBb), whereas its role as pattern recognition molecule mediating complement activation is disputed for decades. Previously, we have found that soluble collectin-12 (sCL-12) synergizes complement alternative pathway (AP) activation. However, whether this observation is C3 dependent is unknown. By application of the C3-inhibitor Cp40, we found that properdin in normal human serum bound to Aspergillus fumigatus solely in a C3b dependent manner. Cp40 also prevented properdin binding when properdin-depleted serum reconstituted with purified properdin was applied, in analogy with the findings achieved by C3- depleted serum. However, when opsonized with sCL-12, properdin bound in a C3-independent manner exclusively via its tetrameric structure and directed in situ C3bBb assembly. In conclusion, a prerequisite for properdin binding and in situ C3bBb assembly was the initial docking of sCL-12. This implies a new important function of properdin in host defence bridging pattern recognition and specific AP activation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007505</institution-id><institution>Kirsten og Freddy Johansens Fond</institution></institution-wrap></funding-source><award-id>Research fund</award-id><principal-award-recipient><name><surname>Ma</surname><given-names>Ying Jie</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004191</institution-id><institution>Novo Nordisk</institution></institution-wrap></funding-source><award-id>Research fund</award-id><principal-award-recipient><name><surname>Garred</surname><given-names>Peter</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008266</institution-id><institution>Købmand I Odense Johan og Hanne Weimann Født Seedorffs Legat</institution></institution-wrap></funding-source><award-id>Research fund</award-id><principal-award-recipient><name><surname>Ma</surname><given-names>Ying Jie</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007469</institution-id><institution>Alfred Benzon Foundation</institution></institution-wrap></funding-source><award-id>Research fund</award-id><principal-award-recipient><name><surname>Ma</surname><given-names>Ying Jie</given-names></name><name><surname>Garred</surname><given-names>Peter</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>John D. Lambris, inventor of patents (Patent Number: 9630992) and/or patent applications 426 (Application Number: 15/126,937) that describe the use of complement inhibitors for therapeutic purposes, the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (i.e., third-generation compstatins) for clinical applications, and the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (i.e., 4[1MeW]7W/POT-4/APL-1 and PEGylated derivatives)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-60908-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>